Orrell C - Search Results

1

Tenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in South Africa.

Jennings L, Robbins RN, Nguyen N, Ferraris C, Leu CS, Dolezal C, Hsiao NY, Mgbako O, Joska J, Castillo-Mancilla JR, Myer L, Anderson PL, Remien RH, Orrell C; ADD-ART team. Jennings L, et al. Among authors: orrell c. AIDS. 2022 Jun 1;36(7):933-940. doi: 10.1097/QAD.0000000000003185. Epub 2022 Feb 16. AIDS. 2022. PMID: 35131960 Free PMC article.

2

Adherence is not a barrier to successful antiretroviral therapy in South Africa.

Orrell C, Bangsberg DR, Badri M, Wood R. Orrell C, et al. AIDS. 2003 Jun 13;17(9):1369-75. doi: 10.1097/00002030-200306130-00011. AIDS. 2003. PMID: 12799558 Clinical Trial.

3

Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines.

Badri M, Bekker LG, Orrell C, Pitt J, Cilliers F, Wood R. Badri M, et al. Among authors: orrell c. AIDS. 2004 May 21;18(8):1159-68. doi: 10.1097/00002030-200405210-00009. AIDS. 2004. PMID: 15166531

4

Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme.

Lawn SD, Bekker LG, Myer L, Orrell C, Wood R. Lawn SD, et al. Among authors: orrell c. AIDS. 2005 Nov 18;19(17):2050-2. doi: 10.1097/01.aids.0000191232.16111.f9. AIDS. 2005. PMID: 16260920 No abstract available.

5

Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design.

Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Lawn SD, et al. Among authors: orrell c. AIDS. 2005 Dec 2;19(18):2141-8. doi: 10.1097/01.aids.0000194802.89540.e1. AIDS. 2005. PMID: 16284464

6

Antiretroviral adherence in a resource-poor setting.

Orrell C. Orrell C. Curr HIV/AIDS Rep. 2005 Nov;2(4):171-6. doi: 10.1007/s11904-005-0012-8. Curr HIV/AIDS Rep. 2005. PMID: 16343374 Review.

7

When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.

Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R. Badri M, et al. Among authors: orrell c. Antivir Ther. 2006;11(1):63-72. Antivir Ther. 2006. PMID: 16518961

8

Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa.

Bekker LG, Myer L, Orrell C, Lawn S, Wood R. Bekker LG, et al. Among authors: orrell c. S Afr Med J. 2006 Apr;96(4):315-20. S Afr Med J. 2006. PMID: 16670804

9

Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation.

Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Lawn SD, et al. Among authors: orrell c. Clin Infect Dis. 2006 Sep 15;43(6):770-6. doi: 10.1086/507095. Epub 2006 Aug 8. Clin Infect Dis. 2006. PMID: 16912954

10

Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment.

Kaplan R, Orrell C, Zwane E, Bekker LG, Wood R. Kaplan R, et al. Among authors: orrell c. AIDS. 2008 Aug 20;22(13):1679-81. doi: 10.1097/QAD.0b013e32830ebcee. AIDS. 2008. PMID: 18670232 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

176 results

Search Page

Filters